FDA Clearance Tracker · P970007
IMX TACROLIMUS II ASSAY
Last checked: Nov 19, 2026Latest source record: Aug 26, 1997 (this decision)Source: openFDAMethods & limitations
Decided
Aug 26, 1997
Approved (reclassified)
Time to decision
189 days
Received Feb 18, 1997. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class II
The decision
- FDA number
- P970007
- Device name
- IMX TACROLIMUS II ASSAY
- Applicant
- Abbott Laboratories
- Applicant location
- Abbott Park, IL
- Received
- Feb 18, 1997
- Decided
- Aug 26, 1997
- Decision
- Approved (reclassified)
- Expedited review
- Yes, flagged as expedited in FDA's record.
- Supplements
- 4 in FDA's data for this PMA. See them on the FDA record
Device type
- Device type
- ENZYME IMMUNOASSAY, TRACROLIMUS (MLM)
- Device class
- Class II
- Regulation
- 21 CFR 862.1678
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for the IMx(R) Tacrolimus II Assay. This device is indicated for use as an in-vitro reagent sytemf or the quantitative determination of tacrolimus and some metabolites in human whole blood as an aid in the management of liver allograft patients receiving tacrolimus therapy.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code MLM (ENZYME IMMUNOASSAY, TRACROLIMUS).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Abbott Laboratories
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Anti-HCV Next510(k)
K262156 · Decided Sep 23, 2026 · 89 days after receipt
Device type: Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus (MZO) · Laboratory Medicine & Pathology
- Anti-HCV Next510(k)
K252424 · Decided Apr 28, 2026 · 270 days after receipt
Device type: Assay, Enzyme Linked Immunosorbent, Hepatitis C Virus (MZO) · Laboratory Medicine & Pathology
- ARCHITECT iGentamicin510(k)
K243500 · Decided Jul 9, 2025 · 239 days after receipt
Device type: Enzyme Immunoassay, Gentamicin (LCD) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.